Stock Code: 600380 Stock Short Name: 健康元
Joincare Pharmaceutical Group Industry Co., Ltd.
2022 Third Quarterly Report
TheBoardof Directors andall DirectorsoftheCompanyherebywarrant that there
are no false representations, misleading statements or material omissions contained in
this announcement and accept legal responsibility for the truthfulness, accuracy and
completeness of the contents hereof.
IMPORTANT NOTICE:
The Board of Directors, the Board of Supervisors and Directors, Supervisors and senior management
of the Company hereby warrant the truthfulness, accuracy and completeness of the contents of this
quarterly report, and that there are no false representations, misleading statements or material
omissions contained herein, and severally and jointly accept legal responsibility.
The person-in-charge of the Company, the person-in-charge of accounting work and the person-in-
charge of the accounting department (the head of the accounting department) hereby warrant the
truthfulness,accuracyandcompletenessofthefinancialinformationcontainedinthisquarterlyreport.
Whether the third quarterly financial statements are audited.
□Yes √No
I. MAJOR FINANCIAL DATA
(I) Major Accounting Date and Financial Indicators
Unit: Yuan Currency: RMB
From the
For the Reporting beginning of the
Item Period YoY change (%) year to the end of YoY change (%)
the Reporting
Period
Revenue 4,447,021,452.61 8.51 13,011,966,738.16 9.04
Net profit attributable to
shareholders of the listed 325,293,433.73 1.23 1,126,561,953.23 11.69
company
Net profit attributable to
shareholders of the listed 312,360,089.27 -2.90 1,116,354,521.30 21.40
company after deduction of
extraordinary gains and losses
Net cash flow from operating N/A N/A 2,608,992,532.97 60.93
activities
Basic earnings per share 0.1748 6.61 0.5983 16.09
(RMB/share)
Diluted earnings per share 0.1739 6.19 0.5971 16.13
(RMB/share)
Weighted average return on 2.74 Decreased by 0.11 9.39 Increased by 0.50
net assets (%) percentage points percentage points
As at the end of the As at the end of the previous year YoY change (%)
Reporting Period
Total assets 34,713,695,364.54 31,103,900,389.29 11.61
Owner's equity attributable to
shareholders of the listed 12,900,492,209.56 11,820,293,656.69 9.14
company
Notes: 1.The “ReportingPeriod” represents the 3-monthperiod fromthe beginningto the end ofthis quarter,
the same below.
2. From July to September 2022, the Company realized net profit attributable to shareholders of the
parent of RMB325 million, of which Joincare excluding Livzon Pharmaceutical Group Inc. (“Livzon Group”)
and Livzon MAB Pharm Inc. (“Livzon MAB”) realized net profit attributable to shareholders of the parent of
approximately RMB217 million, representing a YoY increase of approximately 37%, and the impact of Livzon
MAB on the net profit attributable to shareholders of the parent was approximately negative RMB186 million.
From January to September 2022, the Company realized net profit attributable to shareholders of the parent of
RMB1,127 million, of which Joincare (excluding Livzon Group and Livzon MAB) realized net profit
attributable to shareholders of the parent of approximately RMB638 million, representing a YoY increase of
approximately 42%, and the impact of Livzon MAB on the net profit attributable to shareholders of the parent
was approximately negative RMB325 million.
3. From January to September 2022, the Company realized revenue of RMB7,402 million from
chemical pharmaceuticals, representing a YoY increase of 7.16%, among which, RMB862 million were from
respiratory formulation, representing a YoY increase of 215%; RMB1,151 million were from anti-infective
products, representing a YoY increase of 9.29%; RMB2,646 million were from gastroenterology products,
re
查看PDF原文
